Loading news...
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST.
Review Dentsply's (XRAY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.
DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago.
News Summary Q4 2025 net sales of $961 million increased 6.2% , constant currency sales increased 2.5% Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of tax Q4 2025 adjusted EPS of $0.27 FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry Initiated new capital allocation strategy by eliminating the dividend and redeploying capital toward debt retirement and share repurchases Established new agreements with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec Launched Surity™ Female External Catheter to enter a new market category in the U.S. Appointed three new members to the Board of Directors: James Forbes, former Vice Chairman Investment Bank of Morgan Stanley; Brian McKeon, former CFO of IDEXX Laboratories, Inc.; and Don Zurbay, former CEO of Patterson Dental CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2025.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders.
Besides Wall Street's top-and-bottom-line estimates for Dentsply (XRAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation
As of April 1, Burkhart Dental Supply will represent Dentsply Sirona's full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership is designed to give dental professionals more comprehensive access to the tools they rely on every day, combining digital technologies, clinical products, and local support to help practices streamline workflows and adopt new technology with confidence.
XRAY gears up for Q4 results amid U.S. weakness, tariff headwinds and a lowered outlook as investors watch for signs of stabilization.
DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report)'s stock price gapped up before the market opened on Thursday after Bank of America upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $12.49, but opened at $13.12. Bank of America now has a $17.00 price target on the
Cooper Companies (NASDAQ: COO - Get Free Report) and DENTSPLY SIRONA (NASDAQ: XRAY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Profitability This table compares Cooper Companies and DENTSPLY
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENTSPLY SIRONA (NASDAQ: XRAY - Get Free Report) is projected to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $926.3960 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning
Cibc World Market Inc. reduced its position in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 42.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 536,540 shares of the medical instruments supplier's stock after selling 388,618 shares during the quarter.
DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) has received an average rating of "Reduce" from the fourteen brokerages that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating on the company.
Exploring the Fourth Quarter 2025 13F Filing John Rogers (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh